SOUTH SAN FRANCISCO, Calif., Jan. 3 /PRNewswire-FirstCall/ -- Cell
Genesys, Inc. (Nasdaq: CEGE), today announced that Stephen A. Sherwin, M.D.,
chairman and chief executive officer of Cell Genesys, will present a company
update at the JPMorgan Healthcare Conference in San Francisco, CA that will be
broadcast live over the internet on Monday, January 9, 2006 at 9:00 AM PST.
The webcast will be available on the Investor Relations section of the
Cell Genesys website, http://www.cellgenesys.com . If you are unable to listen to
the live webcast, it will be archived on the site for at least 48 hours
following the presentation. To access the replay, go to the Investor
Relations section of the website.
Cell Genesys is focused on the development and commercialization of novel
biological therapies for patients with cancer. The company is currently
pursuing two clinical stage product platforms -- GVAX(R) cancer vaccines and
oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of
GVAX(R) vaccine for prostate cancer, Phase 2 trials of GVAX(R) vaccines for
leukemia and pancreatic cancer, and a Phase 1 trial of CG0070 oncolytic virus
therapy for bladder cancer and potentially other types of cancer. Cell
Genesys continues to hold equity interests in its two former subsidiaries --
Abgenix, Inc., an antibody products company and Ceregene, Inc., which is
developing gene therapies for neurodegenerative disorders. Cell Genesys is
headquartered in South San Francisco, CA and has its principal manufacturing
operation in Hayward, CA. For additional information, please visit the
company's website at http://www.cellgenesys.com .
Statements made herein about the company, other than statements of
historical fact, including statements about the company's progress, results
and timing of clinical trials and preclinical programs and the nature of
product pipelines are forward-looking statements and are subject to a number
of uncertainties that could cause actual results to differ materially from the
statements made, including risks associated with the success of clinical
trials and research and development programs, the regulatory approval process
for clinical trials, competitive technologies and products, patents,
continuation of corporate partnerships and the need for additional financings.
For information about these and other risks which may affect Cell Genesys,
please see the company's Annual Report on Form 10-K for the year ended
December 31, 2004 dated March 14, 2005 as well as Cell Genesys' reports on
Form 10-Q and 8-K and other reports filed from time to time with the
Securities and Exchange Commission. The company assumes no obligation to
update the forward-looking information in this press release.
Contact: Ina Cu
Investor Relations
650-266-3200
SOURCE Cell Genesys, Inc.
 back to top
Related links:
http://www.cellgenesys.com
CONTACT:
investor relations, Ina Cu of Cell Genesys,
Inc., +1-650-266-3200
|
